SIG-001(Sigilon)

N/A

Report date: 2025/03/25 16:31:35

Base Information

Drug NameSIG-001(Sigilon)

Drug Alias NameLaparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.B-domain deleted human factor VIII (BDD-hFVIII) producing spheres(Sigilon Therapeutics)Sig-001(Sigilon)

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionCell replacementsEnzyme replacementsTissue factor repalcements

TargetsCoagulation factor VII

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermanyUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSigilon Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSigilon Therapeutics Inc

Inactive CompaniesEli Lilly And Company

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A